Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.

ABSTRACT:

Background & aims

The gradual accumulation of hepatic fibrosis in chronic liver disease results in clinical complications. The rate of hepatic fibrosis score progression (RFSP) in predicting clinical outcomes was assessed by extending the 4-year Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C) Trial to include preenrollment liver biopsies.

Methods

The RFSP was calculated from the linear regression slope of Ishak fibrosis score vs time in 457 patients with liver biopsies (≥10-mm length) prior to the HALT-C Trial (575 biopsies) plus 1101 on-study biopsies (total 1676 biopsies). Individual slopes were calculated if duration from first to last biopsy was > 4 years.

Results

The RFSP as average fibrosis score vs average time in intervals (0-3 and >3 year

SUBMITTER: Hoefs JC 

PROVIDER: S-EPMC3773843 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature